Search

Displaying results 1321 - 1330 of 8696 in total
  1. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    allowing for administration in a one-hour infusion twice-a-year following the starting dose. … CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.

  2. Indication

    Early Estrogen Receptor Positive Breast Cancer

    go.drugbank.com/conditions/DBCOND0173171
    Drugs: Goserelin
    Synonyms: Early Estrogen Receptor Positive Breast Cancer
  3. Indication

    Metastatic Estrogen Receptor Positive Breast Cancer

    go.drugbank.com/conditions/DBCOND0129603
    Drugs: Tamoxifen
    Synonyms: Metastatic Estrogen Receptor Positive Breast Cancer
  4. Drug

    Magnesium silicate

    go.drugbank.com/drugs/DB13249
    ApprovedWithdrawn

    [T186] It is known as talc and it presents many uses in the cosmetic industry, food industry and pharmaceutical industry. … It is the magnesium salt of silicic acid containing an unspecified amount of water. The molecular formula can be expressed more clearly as MgSiO3.xH2O.

    Categories: Drugs for Acid Related Disorders
  5. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    Endogenous CNP, first described in 1998, is primarily responsible for the stimulation of chondrocytes and long bone growth via activity at the NPR-B receptor, making it an attractive target in the treatment … approved for the treatment of achondroplasia in both regions.

    Categories: Drugs for Treatment of Bone Diseases
  6. Drug

    Binimetinib

    go.drugbank.com/drugs/DB11967
    ApprovedInvestigational

    with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. … [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients

    Categories: MAP Kinase, antagonists & inhibitors, MAP Kinase Kinase 1, antagonists & inhibitors
  7. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    Despite this difference in activity, the two commercially available forms have been shown to be pharmacokinetically identical and may be used interchangeably with limited differences in efficacy or side … Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein.

    Categories: Detoxifying Agents for Antineoplastic Treatment
  8. Drug

    Carbon monoxide

    go.drugbank.com/drugs/DB11588
    ApprovedInvestigational

    Carbon monoxide is presently used in small amounts in low oxygen modified atmosphere packaging systems (MAP) for fresh meat to stabilize and maintain natural meat color. … The technique was first described 100 years ago, and applied to clinical practice many years after.

    Mixtures: iCOmix 0,28 % / 9,3 % Gas zur medizinischen Anwendung, druckverdichtet, iCOmas 0,3 % / 0,3 % / 0,3 % Gas zur medizinischen Anwendung, druckverdichtet
  9. Drug

    Flotufolastat F-18

    go.drugbank.com/drugs/DB17851
    ApprovedInvestigational

    [A259846] In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive … [A259846,L46731] In patients with recurrent prostate cancer that require localized treatment, the use of <sup>18</sup>F-labeled ligands for positron emission tomography (PET) offers accurate diagnostic

  10. Drug

    Helium

    go.drugbank.com/drugs/DB09155
    ApprovedInvestigationalVet approved

    It is also used as an analytical reagent in diagnostic/imaging tests to detect respiratory function of the patient.

    Mixtures: iCOmix 0,28 % / 9,3 % Gas zur medizinischen Anwendung, druckverdichtet